{"id": "ZOMXxaYAAAAJ", "citedby": 1202, "citedby5y": 918, "hindex": 18, "hindex5y": 17, "i10index": 31, "i10index5y": 28, "coauthors": [], "name": "Joshua Grill", "affiliation": "UC Irvine", "interests": ["Alzheimer", "clinical trial", "recruitment"], "cites_per_year": {"2003": 3, "2004": 7, "2005": 8, "2006": 9, "2007": 8, "2008": 12, "2009": 14, "2010": 14, "2011": 28, "2012": 39, "2013": 56, "2014": 71, "2015": 80, "2016": 106, "2017": 156, "2018": 230, "2019": 231, "2020": 104}, "publications": [{"bib": {"title": "Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:TQgYirikUcIC", "citedby": "108"}, {"bib": {"title": "Transient analgesia evoked by noxious stimulus offset", "year": "2002"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:ULOm3_A8WrAC", "citedby": "101"}, {"bib": {"title": "Age-related and laminar-specific dendritic changes in the medial frontal cortex of the rat", "year": "2002"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:kNdYIx-mwKoC", "citedby": "99"}, {"bib": {"title": "Unmet needs of caregivers of individuals referred to a dementia care program", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:ZeXyd9-uunAC", "citedby": "94"}, {"bib": {"title": "Current therapeutic targets for the treatment of Alzheimer\u2019s disease", "year": "2010"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:u5HHmVD_uO8C", "citedby": "89"}, {"bib": {"title": "Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials", "year": "2010"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:u-x6o8ySG0sC", "citedby": "87"}, {"bib": {"title": "Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:IWHjjKOFINEC", "citedby": "51"}, {"bib": {"title": "Facilitating Alzheimer\u2019s disease research recruitment", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:W7OEmFMy1HYC", "citedby": "42"}, {"bib": {"title": "Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:d1gkVwhDpl0C", "citedby": "40"}, {"bib": {"title": "Communicating mild cognitive impairment diagnoses with and without amyloid imaging", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:70eg2SAEIzsC", "citedby": "27"}, {"bib": {"title": "Effect of study partner on the conduct of Alzheimer disease clinical trials", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:9yKSN-GCB0IC", "citedby": "26"}, {"bib": {"title": "Multilocus genetic profiling to empower drug trials and predict brain atrophy", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:IjCSPb-OGe4C", "citedby": "26"}, {"bib": {"title": "African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:hMod-77fHWUC", "citedby": "25"}, {"bib": {"title": "Risk disclosure and preclinical Alzheimer\u2019s disease clinical trial enrollment", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:zYLM7Y9cAGgC", "citedby": "24"}, {"bib": {"title": "Should we disclose amyloid imaging results to cognitively normal individuals?", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:YsMSGLbcyi4C", "citedby": "24"}, {"bib": {"title": "Novel targets for Alzheimer's disease treatment", "year": "2010"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:_kc_bZDykSQC", "citedby": "23"}, {"bib": {"title": "Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:RGFaLdJalmkC", "citedby": "21"}, {"bib": {"title": "Willingness to be a brain donor: A survey of research volunteers from four racial/ethnic groups", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:GnPB-g6toBAC", "citedby": "19"}, {"bib": {"title": "Why are spousal caregivers more prevalent than nonspousal caregivers as study partners in AD dementia clinical trials?", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:3fE2CSJIrl8C", "citedby": "18"}, {"bib": {"title": "Are patients whose study partners are spouses more likely to be eligible for Alzheimer\u2019s disease clinical trials", "year": "2012"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:UeHWp8X0CEIC", "citedby": "17"}, {"bib": {"title": "Patient and caregiver reactions to clinical amyloid imaging", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:RYcK_YlVTxYC", "citedby": "16"}, {"bib": {"title": "Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:e5wmG9Sq2KIC", "citedby": "16"}, {"bib": {"title": "Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer\u2019s disease clinical trials", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:hFOr9nPyWt4C", "citedby": "15"}, {"bib": {"title": "Attitudes toward clinical trials across the Alzheimer\u2019s disease spectrum", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:ZHo1McVdvXMC", "citedby": "14"}, {"bib": {"title": "Alzheimer\u2019s disease progression by geographical region in a clinical trial setting", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:-f6ydRqryjwC", "citedby": "13"}, {"bib": {"title": "Choosing Alzheimer's disease prevention clinical trial populations", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:Tyk-4Ss8FVUC", "citedby": "13"}, {"bib": {"title": "Commentary on \u201cA roadmap for the prevention of dementia II: Leon Thal Symposium 2008.\u201d Prevention trials in persons at risk for dominantly inherited Alzheimer's disease \u2026", "year": "2009"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:2osOgNQ5qMEC", "citedby": "13"}, {"bib": {"title": "Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a \u2026", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:EUQCXRtRnyEC", "citedby": "12"}, {"bib": {"title": "Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:Wp0gIr-vW9MC", "citedby": "12"}, {"bib": {"title": "Recognizing involuntary emotional expression disorder", "year": "2007"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:qjMakFHDy7sC", "citedby": "12"}, {"bib": {"title": "The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease", "year": "2013"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:ufrVoPGSRksC", "citedby": "11"}, {"bib": {"title": "Recruiting to preclinical Alzheimer's disease clinical trials through registries", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:35N4QoGY0k4C", "citedby": "8"}, {"bib": {"title": "Study partners: essential collaborators in discovering treatments for Alzheimer\u2019s disease", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:b0M2c_1WBrUC", "citedby": "7"}, {"bib": {"title": "Study partners should be required in preclinical Alzheimer\u2019s disease trials", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:dfsIfKJdRG4C", "citedby": "7"}, {"bib": {"title": "Reactions to learning a \u201cnot elevated\u201d amyloid PET result in a preclinical Alzheimer\u2019s disease trial", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:NhqRSupF_l8C", "citedby": "6"}, {"bib": {"title": "Conversion discriminative analysis on mild cognitive impairment using multiple cortical features from MR images", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:ldfaerwXgEUC", "citedby": "6"}, {"bib": {"title": "Frequency and impact of informant replacement in Alzheimer\u2019s disease research", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:9ZlFYXVOiuMC", "citedby": "6"}, {"bib": {"title": "Recruiting the oldest-old for clinical research", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:bFI3QPDXJZMC", "citedby": "5"}, {"bib": {"title": "Constructing a local potential participant registry to improve Alzheimer\u2019s disease clinical research recruitment", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:f2IySw72cVMC", "citedby": "5"}, {"bib": {"title": "Attitudes toward potential participant registries", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:J_g5lzvAfSwC", "citedby": "5"}, {"bib": {"title": "Does study partner type impact the rate of Alzheimer's disease progression?", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:eQOLeE2rZwMC", "citedby": "5"}, {"bib": {"title": "Prevention trials in persons at-risk for dominantly-inherited Alzheimer's disease: opportunities and challenges", "year": "2009"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:mVmsd5A6BfQC", "citedby": "5"}, {"bib": {"title": "A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer\u2019s disease", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:mB3voiENLucC", "citedby": "4"}, {"bib": {"title": "Does Alzheimer\u2019s disease pathologic change underlie subjective cognitive complaints?", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:qUcmZB5y_30C", "citedby": "4"}, {"bib": {"title": "A cry for help: Treating involuntary emotional expression disorder", "year": "2008"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:WF5omc3nYNoC", "citedby": "3"}, {"bib": {"title": "Dendritic stability in a model of adult-onset IGF-I deficiency", "year": "2005"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:KlAtU1dfN6UC", "citedby": "3"}, {"bib": {"title": "Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:M3ejUd6NZC8C", "citedby": "2"}, {"bib": {"title": "Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer\u2019s trials", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:OU6Ihb5iCvQC", "citedby": "1"}, {"bib": {"title": "Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer\u2019s disease: study partner vs. participant accuracy", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:dshw04ExmUIC", "citedby": "1"}, {"bib": {"title": "Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:1sJd4Hv_s6UC", "citedby": "1"}, {"bib": {"title": "A preliminary study of clinical trial enrollment decisions among people with mild cognitive impairment and their study partners", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:abG-DnoFyZgC", "citedby": "1"}, {"bib": {"title": "Participant\u2013Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:maZDTaKrznsC", "citedby": "1"}, {"bib": {"title": "Optimizing effect sizes with imaging enrichment and outcome choices for mild Alzheimer\u2019s disease clinical trials", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:isC4tDSrTZIC", "citedby": "1"}, {"bib": {"title": "Disclosure of amyloid status in the a4 trial", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:_Qo2XoVZTnwC", "citedby": "1"}, {"bib": {"title": "The impact of study partner change in Alzheimer's disease research", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:qxL8FJ1GzNcC", "citedby": "1"}, {"bib": {"title": "Volumetric MRI results of BMS avagacestat in a prodromal AD population", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:4TOpqqG69KYC", "citedby": "1"}, {"bib": {"title": "Correlation between baseline measures of amyloid-positron emission tomography (PET) imaging, cerebral spinal fluid (CSF) biomarkers, and clinical scales in predementia \u2026", "year": "2011"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:_FxGoFyzp5QC", "citedby": "1"}, {"bib": {"title": "Should persons with autosomal dominant AD be included in clinical trials?", "year": "2011"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:Y0pCki6q_DkC", "citedby": "1"}, {"bib": {"title": "Factors Important to Cognitively Normal Adults in Decisions about Alzheimer's Disease Secondary Prevention Trial Participation", "year": "2011"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:hqOjcs7Dif8C", "citedby": "1"}, {"bib": {"title": "Neuropsychiatric symptom profiles in Mild Cognitive Impairment and Alzheimer's disease", "year": "2010"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:MXK_kJrjxJIC", "citedby": "1"}, {"bib": {"title": "Is reluctance to share Alzheimer\u2019s disease biomarker status with a study partner a barrier to preclinical trial recruitment?", "year": "2020"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:p2g8aNsByqUC", "citedby": "0"}, {"bib": {"title": "Racial and ethnic differences in older adults\u2019 willingness to be contacted about Alzheimer's disease research participation", "year": "2020"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:u9iWguZQMMsC", "citedby": "0"}, {"bib": {"title": "Response to \u201cAvoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure\u201d", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:P5F9QuxV20EC", "citedby": "0"}, {"bib": {"title": "Retention of Alzheimer Disease Research Participants", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:KxtntwgDAa4C", "citedby": "0"}, {"bib": {"title": "WHY IS THE STUDY PARTNER REQUIREMENT A BARRIER TO RECRUITMENT IN PRECLINICAL ALZHEIMER\u2019S DISEASE TRIALS?", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:uWQEDVKXjbEC", "citedby": "0"}, {"bib": {"title": "COGNITIVELY IMPAIRED BRAIN HEALTH REGISTRY PARTICIPANTS\u2019ATTITUDES ABOUT THE VALUE OF AMYLOID PET RESULTS", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:SP6oXDckpogC", "citedby": "0"}, {"bib": {"title": "RACIAL AND ETHNIC DIFFERENCES IN PARTICIPANTS\u2019WILLINGNESS TO BE CONTACTED ABOUT RESEARCH PARTICIPATION", "year": "2019"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:UxriW0iASnsC", "citedby": "0"}, {"bib": {"title": "Participant satisfaction with learning Alzheimer's disease clinical trial results", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:pyW8ca7W8N0C", "citedby": "0"}, {"bib": {"title": "No user account? Register for free. Register for free.", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:8k81kl-MbHgC", "citedby": "0"}, {"bib": {"title": "No user account? Register for free. Register for free.", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:5nxA0vEk-isC", "citedby": "0"}, {"bib": {"title": "Disrupted offset analgesia distinguishes patients with chronic pain from healthy controls", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:_xSYboBqXhAC", "citedby": "0"}, {"bib": {"title": "Public Understanding and Opinions regarding Genetic Research on Alzheimer\u2019s Disease", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:nb7KW1ujOQ8C", "citedby": "0"}, {"bib": {"title": "Thank you to our reviewers 2017", "year": "2018"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:lSLTfruPkqcC", "citedby": "0"}, {"bib": {"title": "HOW DO PEOPLE WITH MILD COGNITIVE IMPAIRMENT AND THEIR FAMILY MEMBERS DECIDE WHETHER TO ENROLL IN PRODROMAL ALZHEIMER\u2019S DISEASE CLINICAL TRIALS?", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:rO6llkc54NcC", "citedby": "0"}, {"bib": {"title": "Consent-to-Contact Registry: A New Tool for Accelerating Clinical Research Recruitment at UCI", "year": "2017"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:SeFeTyx0c_EC", "citedby": "0"}, {"bib": {"title": "RACIAL DIFFERENCES IN WILLINGNESS TO ENROLL IN PRECLINICAL ALZHEIMER'S DISEASE CLINICAL TRIALS", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:YFjsv_pBGBYC", "citedby": "0"}, {"bib": {"title": "COMMUNICATING MILD COGNITIVE IMPAIRMENT DIAGNOSIS WITH AND WITHOUT AMYLOID IMAGING: RECOMMENDATIONS FROM AN EXPERT WORKGROUP", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:NMxIlDl6LWMC", "citedby": "0"}, {"bib": {"title": "Student Presentation Participant-Informant Relationship Affects Quality of Life Ratings in Incipient and Clinical Alzheimer's Disease: B119", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:NaGl4SEjCO4C", "citedby": "0"}, {"bib": {"title": "Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer\u2019s disease: results of a \u2026", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:k_IJM867U9cC", "citedby": "0"}, {"bib": {"title": "Optimizing Effect Sizes in Mild Alzheimer\u2019s Disease Clinical Trials (P2. 227)", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:bEWYMUwI8FkC", "citedby": "0"}, {"bib": {"title": "Participant-Informant Relationship Affects Quality of Life Ratings in Incipient and Clinical Alzheimer\u2019s Disease (P2. 226)", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:iH-uZ7U-co4C", "citedby": "0"}, {"bib": {"title": "Attitudes Toward Clinical Trials and Genetic Disclosure in Autosomal Dominant Alzheimer Disease: Implications for Huntington Disease.", "year": "2016"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:r0BpntZqJG4C", "citedby": "0"}, {"bib": {"title": "Attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer\u2019s disease", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:j3f4tGmQtD8C", "citedby": "0"}, {"bib": {"title": "Ethics in Alzheimer's disease prevention clinical trial design", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:4JMBOYKVnBMC", "citedby": "0"}, {"bib": {"title": "The requirement to learn amyloid status is not a barrier to enrollment in preclinical Alzheimer\u2019s disease clinical trials", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:RHpTSmoSYBkC", "citedby": "0"}, {"bib": {"title": "Front & Back Matter", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:M05iB0D1s5AC", "citedby": "0"}, {"bib": {"title": "Unmet needs of caregivers of individuals referred to a dementia care program", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:2P1L_qKh6hAC", "citedby": "0"}, {"bib": {"title": "Consider the source: The implications of informant type on outcome assessments", "year": "2015"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:R3hNpaxXUhUC", "citedby": "0"}, {"bib": {"title": "REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:4DMP91E08xMC", "citedby": "0"}, {"bib": {"title": "COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS", "year": "2014"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:aqlVkmm33-oC", "citedby": "0"}, {"bib": {"title": "Ketogenic medical food consumption in Alzheimer's disease enhances the acute cerebral blood flow response in specific frontocortical and basal ganglia regions", "year": "2012"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:0EnyYjriUFMC", "citedby": "0"}, {"bib": {"title": "Alzheimer's disease patients with adult child study partners are underrepresented in clinical trials and may experience slower cognitive decline", "year": "2012"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:UebtZRa9Y70C", "citedby": "0"}, {"bib": {"title": "A pilot survey to explore attitudes toward primary prevention, secondary prevention and Alzheimer's disease treatment clinical trials", "year": "2012"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:roLk4NBRz8UC", "citedby": "0"}, {"bib": {"title": "Clinical trials in common neurological disorders", "year": "2012"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:LkGwnXOMwfcC", "citedby": "0"}, {"bib": {"title": "The Influence of the Availability of Prevention Trials on Genetic Testing Decisions in Persons At-Risk for Familial Alzheimer's Disease", "year": "2011"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:Se3iqnhoufwC", "citedby": "0"}, {"bib": {"title": "The effects of normal aging and insulin-like growth factor-1 on dendritic geometry", "year": "2004"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:Zph67rFs4hoC", "citedby": "0"}, {"bib": {"title": "Thank You to Our Reviewers in 2018!"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:xtRiw3GOFMkC", "citedby": "0"}, {"bib": {"title": "Our thanks to those who have helped with this issue of Expert Review of Neurotherapeutics. Listed below are the authors, referees and others who have kindly given their time \u2026"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:D03iK_w7-QYC", "citedby": "0"}, {"bib": {"title": "P4-172 DELAYED-START ANALYSES OF SOLANEZUMAB PHASE 3 EXPEDITION STUDIES IN MILD ALZHEIMER\u2019S DISEASE"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:yD5IFk8b50cC", "citedby": "0"}, {"bib": {"title": "Our thanks to all those who have helped with this issue of Expert Review of Anticancer Therapy. Listed below are the authors, referees and others who have kindly given their \u2026"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:HoB7MX3m0LUC", "citedby": "0"}, {"bib": {"title": "Our thanks to those who have helped with this issue of Expert Review of Neurotherapeutics. Listed below are the authors, referees and others who have kindly given their time \u2026"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:pqnbT2bcN3wC", "citedby": "0"}, {"bib": {"title": "Our thanks to those who have helped with this issue of Expert Review of Neurotherapeutics. Listed below are the authors, referees and others who have kindly given their time \u2026"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:g5m5HwL7SMYC", "citedby": "0"}, {"bib": {"title": "Our thanks to those who have helped with this issue of Expert Review of Neurotherapeutics. Listed below are the authors, referees and others who have kindly given their time \u2026"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:HDshCWvjkbEC", "citedby": "0"}, {"bib": {"title": "Mary S. Easton Center for Alzheimer's Disease Research at UCLA Welcomes New Director"}, "source": "citations", "id_citations": "ZOMXxaYAAAAJ:hC7cP41nSMkC", "citedby": "0"}]}